PbRx medicines
High Cost Drugs Excluded From Tariff
A number of high cost drugs, devices, procedures and products have been excluded from the scope of the national tariff of payment by results . Following the re-organisation of the NHS these drugs are commissioned by:
- NHS England or
- the Clinical Commissioning Groups
For a detailed list of the NHS National Tariff Payment System for 2020 to 2021: https://improvement.nhs.uk/resources/national-tariff/
For a detailed list of medicines not reimbursed through the national prices and directly commissioned by NHS England: https://www.england.nhs.uk/wp-content/uploads/2017/04/NHS-England-drugs-list-v15-2020-2021.pdf
And CCGs: https://improvement.nhs.uk/resources/national-tariff/#h2-annexes
NHS England are the responsible commissioners for the management of the Cancer Drugs Fund. For details of the CDF: https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/
For a list of technologies with approved Patient Access Schemes: https://www.nice.org.uk/about/what-we-do/patient-access-schemes-liaison-unit#list-of-arrangements
Commissioning intentions: this serves as notice to all providers of specialised services in England of changes and priorities for the coming year: https://www.england.nhs.uk/commissioning/spec-services/key-docs/
